$RGNX - approaching the end of falling wedge pattern
Analysts forecast $40
Falling wedge pattern approaching it's end
Resistance 1: $13 --> R2: $16
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.03 USD
−263.49 M USD
90.24 M USD
44.85 M
About REGENXBIO Inc.
Sector
CEO
Curran M. Simpson
Headquarters
Rockville
Website
Founded
2008
FIGI
BBG007Z9V591
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Regenxbio hits 7-month high on $1.75bn partnership with AbbVieRegenxbio hits 7-month high following $1.75bn partnership with AbbVie
REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RRGNX: REGENXBIO Inc.
2020-08-25 07:00:00
REGENXBIO Announces FDA Clearance of IND for Phase II Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Going higher - Enough cash + catalyst in 2H, 2020I strongly believe this is going higher - has cash and have good enough catalyst for 2H, 2020 for it to run up. Good luck
RGNX BTFDRGNX sold off 12% today on news of a partial clinical hold on an NVS gene therapy trial using its vector.
After reading the press release I think this was an overreaction and the stock price will bounce back swiftly into RGNX earnings catalyst on 11/08/2019. It is sold off right to the bottom of its
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of RGNX is 7.25 USD — it has increased by 0.27% in the past 24 hours. Watch REGENXBIO Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange REGENXBIO Inc. stocks are traded under the ticker RGNX.
RGNX stock has fallen by −13.25% compared to the previous week, the month change is a −24.64% fall, over the last year REGENXBIO Inc. has showed a −61.42% decrease.
We've gathered analysts' opinions on REGENXBIO Inc. future price: according to them, RGNX price has a max estimate of 52.00 USD and a min estimate of 22.00 USD. Watch RGNX chart and read a more detailed REGENXBIO Inc. stock forecast: see what analysts think of REGENXBIO Inc. and suggest that you do with its stocks.
RGNX reached its all-time high on Jul 10, 2018 with the price of 85.10 USD, and its all-time low was 7.07 USD and was reached on Jul 20, 2016. View more price dynamics on RGNX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
RGNX stock is 3.21% volatile and has beta coefficient of 2.51. Track REGENXBIO Inc. stock price on the chart and check out the list of the most volatile stocks — is REGENXBIO Inc. there?
Today REGENXBIO Inc. has the market capitalization of 366.63 M, it has decreased by −4.76% over the last week.
Yes, you can track REGENXBIO Inc. financials in yearly and quarterly reports right on TradingView.
REGENXBIO Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
RGNX earnings for the last quarter are −1.17 USD per share, whereas the estimation was −1.12 USD resulting in a −4.25% surprise. The estimated earnings for the next quarter are −1.13 USD per share. See more details about REGENXBIO Inc. earnings.
REGENXBIO Inc. revenue for the last quarter amounts to 24.20 M USD, despite the estimated figure of 23.63 M USD. In the next quarter, revenue is expected to reach 23.55 M USD.
RGNX net income for the last quarter is −59.60 M USD, while the quarter before that showed −52.99 M USD of net income which accounts for −12.47% change. Track more REGENXBIO Inc. financial stats to get the full picture.
No, RGNX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 344.00 employees. See our rating of the largest employees — is REGENXBIO Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. REGENXBIO Inc. EBITDA is −227.25 M USD, and current EBITDA margin is −277.93%. See more stats in REGENXBIO Inc. financial statements.
Like other stocks, RGNX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade REGENXBIO Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So REGENXBIO Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating REGENXBIO Inc. stock shows the strong sell signal. See more of REGENXBIO Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.